Get started

Bristol-Myers Squibb (Portugal)

Homepage: bms.com
Alternate name: Bristol-Myers Squibb Farmacêutica Portuguesa SA
ROR: 0223rpe14
OpenAlex ID: I4405254633
Real‐world treatment patterns, resource use and cost burden of multiple myeloma in Portugal
2019 · Luís Antunes, Francisco Rocha‐Gonçalves, et al. · European Journal of Cancer Care · 17
PDF
Cost-Effectiveness of Nivolumab in Patients with Advanced or Metastatic Renal Cell Carcinoma in Portugal
2016 · K Verleger, AJ Almeida, et al. · Value in Health · 5
Cost-Effectiveness Of Ipilimumab In Previously Treated Patients For Advanced Melanoma In Portugal
2013 · M. Radford, P. Cortes, et al. · Value in Health · 5
PDF
Pcn143 Comparison of Adverse Event Costs of Nivolumab+ipilimumab Versus Sunitinib for Previously Untreated Intermediate-/poor-risk Advanced Renal Cell Carcinoma in Portugal
2019 · D. Alves, C. Polanco Sánchez, et al. · Value in Health · 2
PDF
Pcn245 Grade 3/4 Adverse Event (ae) Costs of Nivolumab Versus Dabrafenib + Trametinib as Adjuvant Treatment in Patients With Stage Iii Braf-mutated Cutaneous Melanoma in Portugal
2019 · D. Alves, A. Amadi, et al. · Value in Health · 1
PDF
Pcn23 - Efficiency of Nivolumab Treatment After Platinum Chemotherapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (r/m Scchn) in Spain
2018 · J. Suarez, A. Juarez-Garcia, et al. · Value in Health · 1
Prm146 - Current and Future Trends in Methodologies of Survival Curve Extrapolation in Oncology Accepted by Hta Authorities.
2018 · M Pochopien, B Malcolm, et al. · Value in Health · 1
Prm116 - General Perceptions of Innovative Methods for Survival Extrapolation in Oncology Among Hta in Europe, Canada and Australia
2018 · M Pochopien, M Contente, et al. · Value in Health · 1
Anticoagulation Treatment with VKA in France, Italy, Germany, Spain and United Kingdom. Results from the React AF Study
2013 · J. Carrasco, F.E. Cotté, et al. · Value in Health · 1
PDF
Adherence to Treatment and Persistency in Patients Treated with VKA in France, Italy, Germany, Spain and the United Kingdom
2013 · J. Carrasco, F.E. Cotté, et al. · Value in Health · 1
PCN99 Cost-Effectiveness of Dasatinib versus High-Dose Imatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia Resistant to Standard-Dose Imatinib in Portugal
2011 · J. Darba, L. Kaskens, et al. · Value in Health · 1
Pcn26 Quantifying the Relative Clinical Value of Nivolumab Plus Ipilimumab Vs. Sunitinib in First-line Advanced or Metastatic Renal Cell Carcinoma With the Number Needed to Treat and Number Needed to Harm in Spain and Portugal
2019 · C. Polanco Sánchez, D. Alves, et al. · Value in Health
PDF
Pcv49 Cost-effectiveness Analysis of Apixaban Versus Edoxaban for Stroke Prevention in Non-valvular Atrial Fibrillation Portuguese Patients
2019 · F. de Andrés-Nogales, P.R. Gay-Pobes, et al. · Value in Health
PDF
Pcn229 - Comparison of Sickness Benefit and Sick Leave Duration in Oncology Across Countries
2018 · M. Contente, P. Singh, et al. · Value in Health
PDF
Coste-efectividad de dasatinib frente a dosis altas de imatinib y nilotinib en pacientes con leucemia mieloide crónica resistente a la dosis estándar de imatinib en Portugal
2013 · Josep Darbà, Lisette Kaskens, et al. · PharmacoEconomics Spanish Research Articles
The Use of Oral Anticoagulation Drugs for Stroke Prevention in Nonvalvular Atrial Fibrilation in France, Italy, Germany, Spain and the United Kingdom: Is Current Practice Consistent with the 2012 ESC Recommendations?
2013 · J. Carrasco, F.E. Cotté, et al. · Value in Health
PDF
PIN37 Cost-Effectiveness of Treatment Initiation With Ritonavir-Boosted Atazanavir (ATV/R) and Lopinavir (LPV/R) in Treatment-NaÏve HIV Patients at Different CD4 Levels at Baseline
2012 · B. Verheggen, I. Aldir, et al. · Value in Health
PIN73 Modeling the Long Term Clinical Outcomes and Health Care Cost Impact of Initiating Treatment with Atazanavir/R Compared with Darunavir/R, Lopinavir/R and Efavirenz for HIV-1 Infected Treatment-NaÏve Patients: Country Results for Italy, Spain, Portugal and UK
2011 · P.O. Thuresson, B. Verheggen, et al. · Value in Health
Works count: 18
Citation count: 42
Year
Topic
Type